ZA200705540B - Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation - Google Patents
Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammationInfo
- Publication number
- ZA200705540B ZA200705540B ZA200705540A ZA200705540A ZA200705540B ZA 200705540 B ZA200705540 B ZA 200705540B ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 A ZA200705540 A ZA 200705540A ZA 200705540 B ZA200705540 B ZA 200705540B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- compositions
- treatment
- airway inflammation
- pde4 modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63498204P | 2004-12-13 | 2004-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200705540B true ZA200705540B (en) | 2009-01-28 |
Family
ID=36121316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200705540A ZA200705540B (en) | 2004-12-13 | 2005-12-12 | Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060148882A1 (xx) |
| EP (1) | EP1838294A1 (xx) |
| JP (1) | JP2008523102A (xx) |
| KR (1) | KR20070092276A (xx) |
| CN (1) | CN101111235A (xx) |
| AR (1) | AR052047A1 (xx) |
| AU (1) | AU2005316593A1 (xx) |
| BR (1) | BRPI0519030A2 (xx) |
| CA (1) | CA2590903A1 (xx) |
| IL (1) | IL183858A0 (xx) |
| MX (1) | MX2007006992A (xx) |
| WO (1) | WO2006065814A1 (xx) |
| ZA (1) | ZA200705540B (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| WO2007045980A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| SG10201402158VA (en) * | 2009-02-10 | 2014-07-30 | Celgene Corp | Methods Of Using And Compositions Comprising PDE4 Modulators For Treatment, Prevention And Management Of Tuberculosis |
| BRPI1012770B8 (pt) | 2009-05-14 | 2021-05-25 | Tianjin Hemay Bio Tech Co Ltd | derivados de tiofeno |
| EP2555769B1 (en) | 2010-04-07 | 2022-01-12 | Amgen (Europe) GmbH | Methods for treating respiratory viral infection |
| CN103442698B (zh) | 2010-12-16 | 2016-10-05 | 细胞基因公司 | 难溶性药物的控释口服剂量形式及其用途 |
| MX2013007959A (es) * | 2011-01-10 | 2013-12-06 | Celgene Corp | Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico. |
| JP6132773B2 (ja) * | 2011-01-10 | 2017-05-24 | セルジーン コーポレイション | Ｐｄｅ４及び／又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体 |
| ES2711100T3 (es) * | 2011-03-07 | 2019-04-30 | Celgene Corp | Métodos para tratar enfermedades usando compuestos isoindolina |
| KR101889757B1 (ko) | 2011-04-28 | 2018-08-20 | 셀진 코포레이션 | 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물 |
| BR112015020584A2 (pt) | 2013-03-14 | 2017-07-18 | Celgene Corp | métodos para o tratamento de artrite psoriática usando apremilast |
| ES2733552T3 (es) * | 2014-01-24 | 2019-11-29 | Celgene Corp | Procedimientos para el tratamiento de la obesidad mediante apremilast |
| EP3188745A1 (en) | 2014-08-15 | 2017-07-12 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| RU2743126C9 (ru) * | 2016-08-22 | 2021-04-27 | Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. | Ингибитор pde4 |
| AU2018228541B2 (en) * | 2017-02-28 | 2020-07-16 | Kangpu Biopharmaceuticals, Ltd. | Novel isoindoline derivative, and pharmaceutical composition and application thereof |
| CA3056307A1 (en) * | 2017-03-16 | 2018-09-20 | Takeda Gmbh | Treatment of idiopathic pulmonary fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| KR20090048520A (ko) * | 2002-11-06 | 2009-05-13 | 셀진 코포레이션 | 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물 |
| MXPA05005164A (es) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (+)3-(3, 4-dimetoxi -fenil) -3-(1 -oxo-1, 3-dihidro -isoindol -2-il)- propionamida. |
| JP5269281B2 (ja) * | 2002-12-30 | 2013-08-21 | セルジーン コーポレイション | フルオロアルコキシ置換１，３−ジヒドロイソインドリル化合物およびそれらの医薬としての使用 |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| AU2004319815A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
-
2005
- 2005-12-12 JP JP2007545718A patent/JP2008523102A/ja not_active Abandoned
- 2005-12-12 ZA ZA200705540A patent/ZA200705540B/xx unknown
- 2005-12-12 BR BRPI0519030-4A patent/BRPI0519030A2/pt not_active IP Right Cessation
- 2005-12-12 MX MX2007006992A patent/MX2007006992A/es unknown
- 2005-12-12 WO PCT/US2005/045071 patent/WO2006065814A1/en active Application Filing
- 2005-12-12 EP EP05853888A patent/EP1838294A1/en not_active Withdrawn
- 2005-12-12 AU AU2005316593A patent/AU2005316593A1/en not_active Abandoned
- 2005-12-12 CN CNA2005800476591A patent/CN101111235A/zh active Pending
- 2005-12-12 CA CA002590903A patent/CA2590903A1/en not_active Abandoned
- 2005-12-12 KR KR1020077015958A patent/KR20070092276A/ko not_active Application Discontinuation
- 2005-12-13 US US11/299,702 patent/US20060148882A1/en not_active Abandoned
- 2005-12-13 AR ARP050105222A patent/AR052047A1/es not_active Application Discontinuation
-
2007
- 2007-06-12 IL IL183858A patent/IL183858A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006065814A1 (en) | 2006-06-22 |
| BRPI0519030A2 (pt) | 2008-12-23 |
| AU2005316593A1 (en) | 2006-06-22 |
| CA2590903A1 (en) | 2006-06-22 |
| MX2007006992A (es) | 2007-08-03 |
| AR052047A1 (es) | 2007-02-28 |
| JP2008523102A (ja) | 2008-07-03 |
| EP1838294A1 (en) | 2007-10-03 |
| IL183858A0 (en) | 2007-10-31 |
| US20060148882A1 (en) | 2006-07-06 |
| KR20070092276A (ko) | 2007-09-12 |
| CN101111235A (zh) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183858A0 (en) | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation | |
| IL181896A0 (en) | Methods and compositions for the treatment of hyperlipidemia | |
| HK1190084A1 (zh) | 用於預防和治療補體相關紊亂的 多肽 | |
| EP1883416A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS RELATED TO INFLAMMATION | |
| ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
| ZA200704677B (en) | Compositions and methods for the treatment of autism | |
| EP1786264A4 (en) | CATIONIC ANTISEPTIC COMPOSITIONS AND METHOD FOR THEIR USE | |
| IL178860A (en) | Certain chemical entities, preparations and processes | |
| EP2318033B8 (en) | Compositions for the treatment of pain and/or inflammation | |
| GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
| IL182574A0 (en) | Gpr41 and modulators thereof for the treatment of insulin-related disorders | |
| EP1755589A4 (en) | METHOD OF USING PDE4 MODULATORS AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | |
| IL181369A0 (en) | Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder | |
| EP1814567A4 (en) | USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS | |
| IL187565A0 (en) | Compositions and methods for the treatment or prevention of chemoresistant neoplasia | |
| EP2079526A4 (en) | COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS | |
| AU2003291480A8 (en) | Composition for the prevention and treatment of inflammation of the ear | |
| EP1720563A4 (en) | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | |
| ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
| EP2056857A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION | |
| IL187405A0 (en) | Methods and compositions for the treatment of pain | |
| EP1802350A4 (en) | MODULATION OF NEUROTROPHIC BRAIN DERIVED FACTOR (BDNF) FROM NEVERROGIA IN THE TREATMENT AND PREVENTION OF PAIN | |
| IL198721A0 (en) | Acat inhibitors and their use in the prevention or treatment of fibrosis | |
| SI1812797T1 (sl) | Pripravki in metode zdravljenja ter preprečevanja hiperprolifetarivnih bolezni | |
| IL181777A0 (en) | Gpr43 and modulators thereof for the treatment of metabolic-related disorders |